Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Porcine pseudorabies virus and porcine circovirus type II bivalent vaccine, and applications thereof

A technology of porcine pseudorabies virus and porcine circovirus, applied in the field of vaccines, can solve problems such as differences in immunogenicity, achieve high antibody levels, better safety, and reduce labor costs

Active Publication Date: 2017-03-22
WUHAN KEQIAN BIOLOGY CO LTD
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the continuous mutation of the epidemic strains, there are differences in immunogenicity between the commercially available vaccines and the vaccines prepared by traditional strains, which cannot prevent and control the current epidemic of porcine pseudorabies.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Porcine pseudorabies virus and porcine circovirus type II bivalent vaccine, and applications thereof
  • Porcine pseudorabies virus and porcine circovirus type II bivalent vaccine, and applications thereof
  • Porcine pseudorabies virus and porcine circovirus type II bivalent vaccine, and applications thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Preparation of porcine pseudorabies virus (XF-1 strain) liquid and vaccine:

[0032] 1. Suspension culture of BHK-21 cells in a bioreactor:

[0033] Take 5ml of BHK-21 seed cells preserved in liquid nitrogen, melt rapidly in a 37°C water bath, centrifuge at 1000rpm for 5 minutes, discard the supernatant, resuspend with 100ml of BHK medium containing 2% (v / v) low serum, and transfer to In a 250ml shake flask, culture on a shaker at a constant temperature at 37°C with a rotation speed of 80-100rpm / min for suspension culture for 2 days until the cell density reaches 2.0-4.0×10 6 cells / ml, according to the ratio of 1:4, at 37 ° C, 80 ~ 100 rpm for 2 ~ 3 days, the cells were expanded to a volume of 1000 ml, so that the cell density reached 4.0 ~ 6.0 × 10 6 cells / ml in order to obtain BHK-21 cell suspension.

[0034] Inoculate 1000ml of the BHK-21 cell suspension obtained above into a 10L bioreactor, add 8L of BHK medium containing 2% (v / v) newborn bovine serum, control the c...

Embodiment 2

[0042] Immunogenicity Test of Porcine Pseudorabies Inactivated Vaccine (XF-1 Strain)

[0043] 1. Materials and methods

[0044] 1.1 The experimental animal market purchased 21-25-day-old piglets from a pig farm in Wuhan, and tested the main pathogens and related antibodies. A total of 30 piglets with negative neutralizing antibody against pseudorabies (PRV neutralizing antibody titer not higher than 1:2).

[0045] 1.2 Challenge strain The field strain of porcine pseudorabies virus (XF strain) was derived from Wuhan Keqian Biotechnology Co., Ltd.

[0046] 1.3 Methods The test pigs were randomly divided into 6 groups, 5 heads in each group, and the conditions of each group were as follows:

[0047] The 1st group is porcine pseudorabies inactivated vaccine (XF-1 strain), promptly selects the vaccine that embodiment 1 prepares;

[0048] The second group is the imported live vaccine (Bartha-K61 strain), batch number: 77BN, which was purchased from Spain's Hyperion Biopharmaceuti...

Embodiment 3

[0069] Comparative experiment on the growth and decline of antibodies against several different porcine pseudorabies vaccines

[0070] 1. Test materials and methods

[0071] 1.1 The experimental animal market purchased 21-25-day-old piglets from a pig farm in Wuhan, and tested the main pathogens and related antibodies. A total of 25 piglets with negative neutralizing antibody against pseudorabies (PRV neutralizing antibody titer not higher than 1:2).

[0072] 1.2 Porcine pseudorabies-specific positive serum, with a neutralizing titer of 1:256, was provided by Wuhan Keqian Biotechnology Co., Ltd.

[0073] 1.3 Test method The test pigs were randomly divided into 5 groups, 5 heads in each group, and the grouping conditions were as follows:

[0074] The first group selects the vaccine prepared in Example 1 for porcine pseudorabies inactivated vaccine (XF-1 strain);

[0075] The second group is the imported live vaccine (Bartha-K61 strain), batch number: 77BN, purchased from the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of vaccine, and more specifically relates to a porcine pseudorabies virus and porcine circovirus type II bivalent vaccine, and applications thereof. The porcine pseudorabies virus and porcine circovirus type II bivalent vaccine comprises inactivated porcine pseudorabies virus XF-1 strain, and porcine circovirus type II-WH strain. It is confirmed by the porcine pseudorabies virus and porcine circovirus type II bivalent inactivated vaccine that XF-1 strain can be prepared into combined vaccines used for preventing two or more than two diseases with other well-known antigens in the field of vaccine, a cognition error that concurrent infection of porcine circovirus type II and porcine pseudorabies virus is caused is eliminated, combination application of porcine circovirus type II and porcine pseudorabies virus at an appropriate rate is capable of achieving excellent effect, and vaccine development prospect is promising.

Description

technical field [0001] The invention mainly relates to the technical field of vaccines, in particular to a dual vaccine of porcine pseudorabies virus and porcine circovirus type 2 and its application. Background technique [0002] Pseudorabies is an acute infectious disease caused by pseudorabies virus (Pseudorabies virus, PRV), including a variety of livestock and wild animals. Pigs are the natural host and reservoir of the virus. The disease is characterized by fever, severe itching, encephalomyelitis and severe reproductive impairment. Since 2011, many provinces across the country have used gE gene-deleted live vaccines for large-scale immunization. Weak piglets, stillbirths, mummies, and miscarriages occur in sows in pig farms; gilts and empty sows often appear to return to estrus, repeated infertility or anoestrus; boars often suffer from testicular atrophy and loss of sexual function after infection breeding ability; new piglets have neurological symptoms and death an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/245A61K39/12A61P31/22A61P31/20
CPCA61K39/12A61K2039/5252A61K2039/552A61K2039/55511A61K2039/70C12N2710/16734C12N2750/10034A61K2300/00
Inventor 陈波徐高原周明光方雨林曾爱星陈章表金建云
Owner WUHAN KEQIAN BIOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com